Literature DB >> 17914318

Efficacy of risperidone treatment in Smith-Magenis syndrome (del 17 pll. 2).

Helmut Niederhofer1.   

Abstract

Smith-Magenis syndrome (SMS) is a clinically recognizable multiple congenital anomaly and mental retardation syndrome caused by an interstitial deletion of chromosome 17 pll.2. Although the physical and molecular genetic features of SMS are increasingly well understood, work is more limited on SMS's behavioral phenotype, which includes self-injury, tantrums, aggression, attention deficit, and sleep disturbance. This case-report describes the lowering of the aggression level of a 13 year old individual with SMS.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17914318

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  3 in total

1.  Pharmacological treatment of disruptive behavior in Smith-Magenis syndrome.

Authors:  Gonzalo Laje; Rebecca Bernert; Rebecca Morse; Maryland Pao; Ann C M Smith
Journal:  Am J Med Genet C Semin Med Genet       Date:  2010-11-15       Impact factor: 3.908

2.  Non-invasive ventilation for sleep-disordered breathing in Smith-Magenis syndrome.

Authors:  Victoria Connor; Sizheng Zhao; Robert Angus
Journal:  BMJ Case Rep       Date:  2016-08-05

Review 3.  Smith-Magenis Syndrome-Clinical Review, Biological Background and Related Disorders.

Authors:  Berardo Rinaldi; Roberta Villa; Alessandra Sironi; Livia Garavelli; Palma Finelli; Maria Francesca Bedeschi
Journal:  Genes (Basel)       Date:  2022-02-11       Impact factor: 4.096

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.